Clinical Trial: CBD Administration Mitigates Stress Levels in Subjects with a Clinical High Risk of Psychosis
London, United Kingdom: The short-term administration of cannabidiol (CBD) is associated with reduced stress levels in subjects diagnosed with a clinically high risk (CHR) of psychosis, according to clinical trial data published in the journal Psychopharmacology. A team of investigators from Italy, the Netherlands, and the United Kingdom assessed the effects of CBD administration on experimentally-induced stress in a randomized, placebo-controlled trial.
Clinical Trial: CBD Administration Mitigates Stress Levels in Subjects with a Clinical High Risk of Psychosis
